CN1027136C - 伤口的愈合 - Google Patents
伤口的愈合 Download PDFInfo
- Publication number
- CN1027136C CN1027136C CN88109273A CN88109273A CN1027136C CN 1027136 C CN1027136 C CN 1027136C CN 88109273 A CN88109273 A CN 88109273A CN 88109273 A CN88109273 A CN 88109273A CN 1027136 C CN1027136 C CN 1027136C
- Authority
- CN
- China
- Prior art keywords
- pdgf
- tgf
- wound
- purification
- people
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000029663 wound healing Effects 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 230000035876 healing Effects 0.000 claims abstract description 10
- 238000000746 purification Methods 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 15
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 102000013275 Somatomedins Human genes 0.000 claims description 7
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 abstract description 58
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 abstract description 58
- 101800004564 Transforming growth factor alpha Proteins 0.000 abstract description 30
- 241000124008 Mammalia Species 0.000 abstract description 4
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 abstract 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 29
- 206010052428 Wound Diseases 0.000 description 23
- 208000027418 Wounds and injury Diseases 0.000 description 23
- 101710103494 Platelet-derived growth factor subunit B Proteins 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 239000000833 heterodimer Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 5
- 101710103506 Platelet-derived growth factor subunit A Proteins 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000008521 reorganization Effects 0.000 description 5
- 239000012064 sodium phosphate buffer Substances 0.000 description 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000005081 epithelial layer Anatomy 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000005514 radiochemical analysis Methods 0.000 description 2
- 229940047431 recombinate Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000767 hemotoxin Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/02—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents specially adapted to protect contents from mechanical damage
- B65D81/05—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents specially adapted to protect contents from mechanical damage maintaining contents at spaced relation from package walls, or from other contents
- B65D81/051—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents specially adapted to protect contents from mechanical damage maintaining contents at spaced relation from package walls, or from other contents using pillow-like elements filled with cushioning material, e.g. elastic foam, fabric
- B65D81/052—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents specially adapted to protect contents from mechanical damage maintaining contents at spaced relation from package walls, or from other contents using pillow-like elements filled with cushioning material, e.g. elastic foam, fabric filled with fluid, e.g. inflatable elements
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mechanical Engineering (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Packages (AREA)
Abstract
通过给哺乳动物涂敷一种组合制剂使哺乳动物外伤愈合、骨骼再生,该组合制剂包含纯化的血小板衍生的生长因子和α转移生长因子。
Description
本发明有关愈合伤口。
生长因子是能刺激一定数目靶细胞的多肽激素。生长因子的例子包括:血小板衍生的生长因子(PDGF)、胰岛素类生长因子(IGF-I)、β转移生长因子(TGF-β)、α转移生长因子(TGF-α)、皮肤生长因子(FGF)、和成纤维细胞生长因子(FGF)。PDGF是一种在循环血小板颗粒中可以找到的热稳定的阳离子蛋白质,据知循环血小板颗粒能刺激体外蛋白质合成和通过成纤维细胞的胶原生成。还知道,它对成纤维细胞起体外***素和趋化剂的作用,还起平滑的肌肉血胞的作用。
已有人提出使用PDGF来促进体内伤口愈合的建议。例如,Grotendorst(1984)J.Trauma24:549-52描述了:将PDGF加到Hunt-Schilling线网室(该室中浸入了胶原凝胶),并植入小鼠的背部;结果发现,PDGF增加了新合成的胶原量。但是,只使用PDGF,或者PDGF与EGF和FGF联合使用,Leitzel等人(1985)J.Dermatol.Surg.Oncol.11:617-22却不能加快大田鼠内普通伤口的愈合速度。
Michaeli等人(1984)在“Soft and Hard Tissue Repair”一书中(Hunt,T.K.等编,纽约、Praeger出版人,PP380-394)报告说,敷用从富血小板的血浆获得的部分纯的PDGF制剂刺激了在将其植入兔角膜时的血管生成。因为PDGF不是血管生长因子,因此研究人员建议,在它们的部分纯PDGF制剂中可能存在一种未知的因子,该未知因子引起血管生长效应。
Schultz,G.S.等人(1984)在“Science”中报告:对猪的部分厚度的皮肤烧伤部位进行局部敷用TGF-α,和未被处理的烧伤部位相比,加速了皮肤的再生过程。
一般来说,本发明的特点是通过给伤口敷用有效剂量的组合制剂来愈合哺乳动物(例如病人)的外伤,该制剂包括纯化的PDGF和纯化的TGF-α的组合。TGF-α最好是人的TGF-α,但是也可以是其它哺乳类的TGF-α,例如鼠的。TGF-α可以从天然源分离出来,通过重组体细胞或固相肽合成来制取TGF-α则更好。本发明的组合制剂通过促进上皮和连接组织的生长以及整个蛋白质和胶原的合成来帮助伤口的愈合,至少是部分愈合。使用本发明的组合制剂进行伤口愈合比不经治疗(即不敷用外原剂)、或经过只使用纯化的PDGF的治疗或只使用纯化的TGF-α的治疗得到的伤口愈合效果都更加有效。
在本发明的最佳实施例中,该组合制剂的制备方法是,在一种药物学上允许的载体物质内,例如在市场上可买到的惰性凝胶或液体(如补充了白蛋或甲基纤维素的盐水)内,将纯化的PDGF和TGF-α(两者皆可在市场上购到)组合在一起。组合纯化的PDGF和TGF-α的最佳重量比在1∶4和25∶1之间,在1∶2和10∶1之间较好,并且1∶1或2∶1则更好些。纯化的PDGF可以从人类的血小板中获得,或者通过重组的DNA(脱氧核糖核酸)技术得到。因此,谈到术语“PDGF”,我们指的是哺乳动物的血小板衍生物和重组体两者,指的是灵长类血统较贴切;该灵长类是人类则最贴切,但也可以是黑猩猩或其它的灵长类。重组的PDGF可以是重组的异二聚体,它是通过将对两个亚单体编码的DNA序列***被培养的原核细胞或真核细胞中制得的,然后让这些细胞去处理这些被转译的亚单体从而即形成了异二聚体,或者将只对一个亚单体(最好是β或“2”链)编码的DNA***这些细胞中,然后对其进行培养从而得到异二聚体的PDGF(PDGF-1或PDGF-2异二聚体)。
这里所用的术语“纯化的”指的是,PDGF或TFG-α在与其它物质混合前按重量计占95%或更高些的PDGF或TGF-α,即这样的PDGF或TGF-α基本上不含本来就与之相关的糖类、酯或其它蛋白质。
对于每一种PDGF和TGF-α组分,一种纯
化在蛋白质制剂一般来说在聚丙烯酰胺凝胶中都要产生一个主带。在本发明的组合制剂中使用的纯化PDGF或TGF-α最好达到通过氨基末端氨基酸序列分析方法测定的纯度。
本发明的组合制剂对于哺乳动物外伤的愈合提供了一种快速有效的方法,例如对于褥疮、裂伤和烧伤的治疗。和自然愈合(即不使用任何外原剂)或只使用纯PDGF或只使用TGF-α相比,该组合制剂加速了连接组织的生成。和只使用纯PDGF不同,该组合制剂促进了新的连接组织和上皮组织两者的显著增长。其所得到的上皮层比自然愈合或只使用TGF-α生长出来的上皮层厚,并且还包含更多的将上皮层连到新连接组织的上皮突起;这样,就使上皮层的粘结更加牢固并且使其得到了保护。
本发明的其它特点和优点将从下述对最佳实施例的描述中和权利要求书中变得更加清楚。
我们现在描述本发明的最佳实施例。
根据本发明用PDGF/TGF-α混合物来治疗外伤,如褥疮和烧伤,该混合物是通过组合纯PDGF和TGF-α制备出来的。从Peninsula实验室(Belmont,CA)可以买到化学合成的人和鼠的TGF-α。从人体血小板衍生得到的纯化PDGF和纯化重组的PDGF可从PDGF公司(Boston,MA)、Collaborative研究中心(Waltham,MA)和Amgen公司(Thousand Oaks,CA)买到。纯化PDGF也可按下述方法制得。
将500至1000单位的洗过的人体血小板粒悬浮于1M Nacl(每个血小板单位2ml)中,并将其在100℃加热15分钟。然后通过离心来分离该上清液,并用1M Nacl两次提取沉淀物。
该提取物靠0.08M NaCl-0.01M磷酸钠缓冲液(pH7.4)进行结合和透析,并在4℃和与该缓冲液平衡的CM-Sephadex C-50混合一夜。然后将该混合物倒入一个柱(5×100cm)中,用0.08MNaCl-0.01M磷酸钠缓冲液进行大面积的清洗,并且在要收集其中的10ml部分时用1M Nacl进行洗提。
有效部分靠0.3M NaCl-0.01M磷酸钠缓冲液(PH7.4)进行汇集和透析,然后进行离心,并在4℃时使其通过与0.3M NaCl-0.01M磷酸钠缓冲液(PH7.4)平衡的2.5×25cm的Blue Sepharose(Pharmacia)柱。之后用该缓冲液清洗该柱,并且用1M NaCl和乙二烯乙醇的1∶1溶液洗提部分纯化的PDGF。
经部分地纯化了的PDGF部分用1M NaCl洗提(1∶1),并且靠1M醋酸透析,然后进行冻干。冻干后的样品被溶于0.8M NaCl-0.01M磷酸钠缓冲液(PH7.4)中,然后让其通过与该缓冲液平衡的1.2×40cm的CM-Sephadex C-50柱。然后借助于NaCl的变化梯度(0.08M至1M)对PDGF进行洗提。
该有效部分靠1M醋酸组合、透析,并且予以冻干,然后将其溶解在少量的1M醋酸中。将其中的0.5ml部分加到与1M醋酸平衡的1.2×100cmBiogel P150柱(100至200个网眼)中。在要收集2ml部分时,用1M醋酸洗提PDGF。
每一个包含100至200mg蛋白质的有效部分被冻干,并将其溶解在100ml的0.4%三氟醋酸中,并使之在苯基的Bondapak柱(Waters)中经受反相的高性能液体层析法处理。用线性的乙腈梯度(0至60%)的洗提即产生了纯PDGF。
可按下述方法制备通过重组的DNA技术制得的PDGF:
从人体血小板得到的血小板衍生增长因子(PDGF)包含两个多肽序列(PDGF-1和PDGF-2;Antoniades,H.N.和Hunkapiller,M.(1983)Science 220∶963-965)。PDGF-1是由位于染色体7中的基因编码的(Betsholtz,C.等人,Nature320∶695-699),PDGF-2是由位于染色体22(Dalla-Favera,R.(1982)Science218∶686-688)的病态致肿瘤基因编码的(Doolittle,R.等人(1983)Science221∶275-277)。病态致肿瘤基因对与PDGF-2多肽紧密相关的猿肉瘤病毒(SSV)的转移蛋白质进行编码。人类的细胞的C-病态也对PDGF-2链进行编码(Rao,C.D.等人(1986),Proc.Natl.Acad.Sci.USA 83∶2392-2396)。由于PDGF的两个多肽链是由位于不同的染色体中的两个不同基因编码的,所以存在下述可能性:人的PDGF由PDGF-1和PDGF-2的一种由双硫醚连接的异二聚体组成,或者是两种单二聚体(PDGF-1单二聚体和PDGF-2单二聚体)的一种混合物,或者是包括异二聚体和两个单二聚体的一种混合物。
受猿的肉瘤病毒感染的、正在培养中的哺乳动物细胞(含对PDGF-2链编码的基因)显示出PDGF-2多肽的合成,并且将其处理成双硫醚连接的单二聚体(Robbims,K.等人(1983)Nature305∶605-608)。此外,PDGF-2单二聚体与抗人体PDGF升高的抗血清发生反应。再有,分泌的PDGF-2单二聚体的功能性在下述方面与血小板衍生的PDGF类似:它刺激了被培养的成纤维细胞中的DNA合成,它在185kd细胞膜蛋白质的酪氨酸基上导致了磷酸化,并且为了束缚到特殊的细胞表面PDGF受体上能和人体的(125I)-PDGF相竞争(Owen,A.等人(1984)Science225∶54-56)。对于从培养的正常人体细胞(如人体的动脉内皮细胞)衍生的病态/PDGF-2基因产物、或者从表达病态/PDGF-2基因的人体恶性肿瘤细胞衍生的上述基因产物,也表示出类似的性质(Antoniades,H.等人(1985)Cancer Cells3∶145-151)。
通过使用表达媒介动物将C-病态/PDGF-2基因的CDNA细胞素引入到小鼠细胞,来获得重组的PDGF-2单二聚体(这里称之为重组的PDGF)。用于表达的C-病态/PDGF-2细胞素是从正常人体培养的内皮细胞得到的(Collians,T.等人(1985)Nature216∶748-750)。
为确定PDGF/TGF-α混合物对促进伤口愈合的效果,进行了下述试验。
让重量在10到15公斤的小白约克夏猪(Parson农场,Hadley,MA)在术前禁食至少六小时,然后进行麻醉。在无菌状态下,对其背部和胸部剪毛、剃净、并用温和的肥皂水洗净。然后用70%酒精对要做成伤口的部位消毒。
用一种改进的Castroviejo电植皮刀(Storz,St.Louis,Mo,由Brownells公司改进)造成1cm×2cm、深度为0.5mm的一些伤口。这些伤口系完全除去了上皮,并除去其真皮下方的一部分(可与二度烧伤相比拟)。各个伤口之间至少由15mm未受伤的皮肤隔开。将接受相同治疗的伤口编成一组,并且与另一些组隔开至少3cm。不接受生长因子治疗的伤口与接受这种治疗的伤口至少隔开10cm。
这些伤口用单次敷用悬浮在生物凝胶中的下述生长因子进行治疗的:1)单独使用500ng纯人体PDGF(通过高性能液体层析法纯化的)或重织的PDGF;2)与下述的每一种进行组合的500ng纯重组的PDGF:a)500ng人体的TGF-α;b)500ng鼠的TGF-α;3)单独使用500ng人或鼠的TGF-α。
在制作了伤口之后的第3天至第10天取活组织检查标本。将用于组织学评价的活组织检查标本取成楔形,约3mm深,并将其放入10%的***中。使用一种电植皮刀来获取用于放化分析和自动射线照相的标本。标本的最终尺寸为1.5mm×10mm×1.5mm。对于进行放化分析的每个伤口收集三个标本,而对于自动射线,对每个伤口收集两个标本。在提取标本之后,将标本贮存在补充了10%牛胎儿血清的冷的EMEM(Eagle′s Modified Essential Medium)介质中。对活组织检查标本进行如下的分析:
组织学的评价
使用标准的石蜡浸渗和植入技术来制备组织标本。制作4微米切片并使用过滤的Harris血毒素(hemotoxylin)和乙醇酒精进行染色;然后在显微镜下进行观察。由两个研究人员在整个这些切片的等分布点上对所有标本进行随意的计数。使用置于显微镜的目镜中的网格对上皮和连接组织层的宽度进行计数;通过使用在相同条件下进行观测的一个测微仪,将测量结果转换为毫米。
DNA和蛋白质的测定
通过使用对Labarca等人(1980)在Anal.Biochem.120∶344-52中的方法的改进方法来进行DNA测定。将在浓缩的氢氧化铵中的50ul等分试样的组织提取物加到400μl的缓冲液中,该缓冲液中含1M磷酸钠和2M氯化钠(pH7.0);使用HCl将最终溶液的pH值调节到7.4。之后,使最终的溶液体积为500μl,同时维持pH值为7.4。然后,将该溶液加到含Hoesht染剂(1.14mg/ml)的2.5ml的被缓冲的溶液(0.05M磷酸钠,2M氯化钠,PH为7.4)中。在352nm的激发波长处激发了荧光并且在454nm测到了辐射。使用通过相同的治疗方法制备的小牛胸腺DNA来绘制标准曲线。
通过Bradford方法(Bradford(1976),Anal.Biochem.72∶248-54)来测量在浓缩的氢氧化铵中组织提取物的蛋白质浓度,其中以牛血清蛋白作为标准。
结果
组织学评价结果表明,和不接受任何治疗、或和单独使用人或鼠TGF-α治疗、或和单独使用纯PDGF治疗的伤口相比,用纯化的人体PDGF或重组的PDGF和化学合成的人或鼠的TGF-α的组合进行治疗的伤口具有较厚的连接组织和上皮层,并且具有与这些层相连的更大范围的上皮突起。
PDGF/TGF-α治疗的伤口具有较大的DNA、蛋白质和胶原含量。
剂量
为了确定纯化的PDGF的合适剂量,要重复上述这些实验,只是这些伤口是用弥散在30μi生物相容凝胶中的、每平方毫米伤口2.5ng、5.0ng和10ng的纯化PDGF的等价物进行治疗的。结果表明,在PDGF含量是5.0ng/cm2或更高些时得到的效果最佳。
为了确定纯PDGF加TGF-α的适当剂量,按上述方法对组合制剂进行估计,其中PDGF与TGF-α的重量比范围为自1∶10∶至25∶1。在重量比范围在1∶1和2∶1之间得到的结果最佳。
Claims (3)
1、一种用于愈合伤口的组合物的制备方法,包括按1∶4和25∶1之间的一个重量比混合纯化的血小板衍生物的生长因子和纯化的α转化生长因子,所述生长因子的混合物再与一种药用载体混合。
2、一种如权利要求1所述的方法,其中所说的重量比在1∶2和10∶1之间。
3、一种如权利要求1所述的方法,其中所说的重量比约为1∶1或2∶1。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/136,399 US4874746A (en) | 1987-12-22 | 1987-12-22 | Wound headling composition of TGF-alpha and PDGF |
US136,399 | 1987-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1036332A CN1036332A (zh) | 1989-10-18 |
CN1027136C true CN1027136C (zh) | 1994-12-28 |
Family
ID=22472686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN88109273A Expired - Lifetime CN1027136C (zh) | 1987-12-22 | 1988-12-21 | 伤口的愈合 |
Country Status (14)
Country | Link |
---|---|
US (1) | US4874746A (zh) |
EP (1) | EP0394349B1 (zh) |
JP (2) | JPH03501973A (zh) |
KR (1) | KR900700128A (zh) |
CN (1) | CN1027136C (zh) |
CA (1) | CA1322164C (zh) |
DE (1) | DE3885300T2 (zh) |
DK (1) | DK175947B1 (zh) |
IE (1) | IE61283B1 (zh) |
MX (1) | MX164966B (zh) |
NZ (1) | NZ227429A (zh) |
OA (1) | OA09129A (zh) |
WO (1) | WO1989005656A1 (zh) |
ZA (1) | ZA889594B (zh) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4849407A (en) * | 1986-08-13 | 1989-07-18 | Zymogenetics, Inc. | Biologically active mosaic proteins |
US5556620A (en) * | 1985-02-05 | 1996-09-17 | Cetus Oncology Corporation | Use of recombinant colony stimulating factor-1 to enhance wound healing |
US5422105A (en) * | 1985-02-05 | 1995-06-06 | Cetus Oncology Corporation | Use of recombinant colony stimulating factor 1 |
US5104650A (en) * | 1985-02-05 | 1992-04-14 | Cetus Corporation | Uses of recombinant colony stimulating factor-1 |
US5474982A (en) * | 1986-08-13 | 1995-12-12 | Zymogenetics, Inc. | PDGF analogs and methods of use |
US5366081A (en) | 1987-08-26 | 1994-11-22 | United States Surgical Corporation | Packaged synthetic absorbable surgical elements |
US5222978A (en) | 1987-08-26 | 1993-06-29 | United States Surgical Corporation | Packaged synthetic absorbable surgical elements |
US5226912A (en) | 1987-08-26 | 1993-07-13 | United States Surgical Corporation | Combined surgical needle-braided suture device |
US5472702A (en) * | 1987-08-26 | 1995-12-05 | United States Surgical Corporation | Sterilization of growth factors |
US5306289A (en) * | 1987-08-26 | 1994-04-26 | United States Surgical Corporation | Braided suture of improved characteristics |
US5654267A (en) * | 1988-12-20 | 1997-08-05 | La Jolla Cancer Research Center | Cooperative combinations of ligands contained within a matrix |
JPH04504216A (ja) * | 1989-03-31 | 1992-07-30 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・ミシガン | 細胞の特定部位点滴注入または細胞の部位特異的形質転換による疾患の治療及び該治療のためのキット |
US5698531A (en) * | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US7238673B2 (en) * | 1989-03-31 | 2007-07-03 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
WO1990014069A2 (en) * | 1989-05-12 | 1990-11-29 | The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University | Keratinocyte autocrine factor |
US5246104A (en) * | 1989-08-01 | 1993-09-21 | United States Surgical Corporation | Molded suture retainer |
US5359831A (en) | 1989-08-01 | 1994-11-01 | United States Surgical Corporation | Molded suture retainer |
US5035887A (en) * | 1989-09-07 | 1991-07-30 | Institute Of Moelcular Biology, Inc. | Wound healing composition of IL-1 and PDGF or IGF-1 |
JPH04352800A (ja) * | 1990-10-26 | 1992-12-07 | Childrens Medical Center Corp:The | 平滑筋***促進因子 |
US5955436A (en) * | 1990-11-20 | 1999-09-21 | Alcon Laboratories, Inc. | Use of platelet derived growth factor to enhance wound healing |
DE69132918T2 (de) * | 1990-11-27 | 2002-10-31 | American National Red Cross, Washington | Gewebeabdeckung und wachstumsfaktor enthaltende verbindungen zur förderung beschleunigter wundheilung |
US6559119B1 (en) | 1990-11-27 | 2003-05-06 | Loyola University Of Chicago | Method of preparing a tissue sealant-treated biomedical material |
US6197325B1 (en) * | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6117425A (en) * | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
US7196054B1 (en) | 1990-11-27 | 2007-03-27 | The American National Red Cross | Methods for treating wound tissue and forming a supplemented fibrin matrix |
US5360790A (en) * | 1990-12-11 | 1994-11-01 | The Regents Of The University Of Michigan | Method and formulations for the therapy of acute renal failure |
CA2059245C (en) * | 1991-02-08 | 2004-07-06 | Michael P. Chesterfield | Method and apparatus for calendering and coating/filling sutures |
US5149691A (en) * | 1991-03-12 | 1992-09-22 | Creative Biomolecules, Inc. | Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone |
WO1992018153A1 (en) * | 1991-04-12 | 1992-10-29 | Creative Biomolecules, Inc. | Method of treating gastrointestinal ulcers with platelet derived growth factor |
AU3062392A (en) * | 1991-11-04 | 1993-06-07 | Novo Nordisk A/S | Pdgf gel formulation |
US5302397A (en) * | 1991-11-19 | 1994-04-12 | Amsden Brian G | Polymer-based drug delivery system |
CA2134073A1 (en) * | 1992-04-23 | 1993-11-11 | Ze'ev Shaked | Bioadhesive aqueous mineral oil emulsion ointment base, topical pharmaceutical compositions comprising same and their use in wound healing |
JPH08501203A (ja) * | 1992-06-03 | 1996-02-13 | ケイス・ウエスタン・リザーブ・ユニバーシティー | 生理活性物質を連続的に適用するための包帯 |
FR2691911B1 (fr) * | 1992-06-05 | 1994-11-25 | Delmas Olivier | Dispositif permettant l'obtention d'un surnageant de thrombocytes activés, procédé mettant en Óoeuvre le dispositif et surnageant obtenu. |
FR2696095B1 (fr) * | 1992-09-30 | 1994-11-25 | Inoteb | Colle biologique à base de protéines coagulables par la thrombine, enrichie en facteurs plaquettaires, sa préparation et son application. |
US6040431A (en) * | 1995-06-07 | 2000-03-21 | Stryker Corporation | Single chain analogs of the TGF-β superfamily (morphons) |
US6321109B2 (en) | 1996-02-15 | 2001-11-20 | Biosense, Inc. | Catheter based surgery |
US6443974B1 (en) | 1996-07-28 | 2002-09-03 | Biosense, Inc. | Electromagnetic cardiac biostimulation |
US6762336B1 (en) | 1998-01-19 | 2004-07-13 | The American National Red Cross | Hemostatic sandwich bandage |
ES2293473T3 (es) | 1998-02-05 | 2008-03-16 | Biosense Webster, Inc. | Administracion intracardiaca de farmaco. |
US20030129750A1 (en) * | 1998-02-05 | 2003-07-10 | Yitzhack Schwartz | Homing of donor cells to a target zone in tissue using active therapeutics or substances |
US20030113303A1 (en) * | 1998-02-05 | 2003-06-19 | Yitzhack Schwartz | Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances |
US6992066B2 (en) * | 1998-10-16 | 2006-01-31 | Zimmer Orthobiologics, Inc. | Povidone-containing carriers for polypeptide growth factors |
US7087577B2 (en) * | 1998-10-16 | 2006-08-08 | Zimmer Orthobiologies, Inc. | Method of promoting natural bypass |
US6663870B2 (en) * | 1998-12-07 | 2003-12-16 | Zymogenetics, Inc. | Methods for promoting growth of bone using zvegf3 |
JP2002543096A (ja) * | 1999-04-26 | 2002-12-17 | ステム セル ファーマシューティカルズ,インコーポレーテッド | TGF−αポリペプチド、機能性断片およびそれらの利用法 |
US20020099008A1 (en) | 1999-04-26 | 2002-07-25 | Daniel R. Twardzik | Method for stimulating hematopoiesis using tgf-alpha |
US6468543B1 (en) | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
US20020193301A1 (en) * | 1999-08-19 | 2002-12-19 | Stem Cell Pharmaceuticals, Inc. | TGF-alpha polypeptides, functional fragments and methods of use therefor |
US6677307B2 (en) | 1999-08-19 | 2004-01-13 | Kaleidos Pharma, Inc. | TGF-α polypeptides, functional fragments and methods of use therefor |
US6815418B2 (en) * | 1999-08-19 | 2004-11-09 | Kaleidos Pharma, Inc. | TGF-α polypeptides, functional fragments and methods of use therefor |
WO2002024148A2 (en) * | 2000-09-22 | 2002-03-28 | Stem Cell Pharmaceuticals Inc. | Method or treatment of tumors using transforming growth factor-alpha |
US6648911B1 (en) | 2000-11-20 | 2003-11-18 | Avantec Vascular Corporation | Method and device for the treatment of vulnerable tissue site |
US7622562B2 (en) * | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
US7241874B2 (en) * | 2002-06-26 | 2007-07-10 | Zimmer Ortho Biologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
WO2004024195A1 (en) * | 2002-09-10 | 2004-03-25 | American National Red Cross | Hemostatic dressing |
US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
EP1951327A2 (en) | 2005-11-17 | 2008-08-06 | Biomimetic Therapeutics, Inc. | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
WO2007092622A2 (en) | 2006-02-09 | 2007-08-16 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating bone |
US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
JP5484047B2 (ja) | 2006-06-30 | 2014-05-07 | バイオミメティック セラピューティクス, エルエルシー | 回旋筋腱板傷害を処置するためのpdgf−生体マトリックス組成物および方法 |
WO2008019126A2 (en) * | 2006-08-04 | 2008-02-14 | Stb Lifesaving Technologies, Inc. | Process for production of solid wound dressing |
EP2086598B1 (en) | 2006-11-03 | 2015-05-27 | BioMimetic Therapeutics, LLC | Compositions and methods for arthrodetic procedures |
WO2009020612A1 (en) * | 2007-08-06 | 2009-02-12 | Stb Lifesaving Technologies, Inc. | Methods and dressing for sealing internal injuries |
PT2185197T (pt) * | 2007-08-22 | 2019-01-21 | Noveome Biotherapeutics Inc | Novas composições de solução contendo fator celular e sua utilização para o tratamento de feridas |
US8282963B2 (en) * | 2007-10-15 | 2012-10-09 | The Regents Of The University Of Colorado, A Body Corporate | Methods for extracting platelets and compositions obtained therefrom |
CN102014977B (zh) | 2008-02-07 | 2015-09-02 | 生物模拟治疗有限责任公司 | 用于牵引成骨术的组合物和方法 |
BRPI0918611B8 (pt) | 2008-09-09 | 2021-06-22 | Biomimetic Therapeutics Inc | composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit |
US8734854B2 (en) | 2009-07-09 | 2014-05-27 | Orogen Biosciences Inc. | Process for removing growth factors from platelets |
CN107080834A (zh) | 2010-02-22 | 2017-08-22 | 生物模拟治疗有限责任公司 | 用于治疗腱病的血小板衍生生长因子组合物和方法 |
EP3206670A4 (en) | 2014-10-14 | 2018-06-20 | Samuel Lynch | Compositions for treating wounds |
WO2020031204A1 (en) | 2018-08-08 | 2020-02-13 | Sree Chitra Tirunal Institute For Medical Science And Technology | Recombinant tgf α for wound healing purposes, and the process thereof |
CN110790822B (zh) * | 2019-11-21 | 2021-04-06 | 南开大学 | 可模拟血小板衍生因子生物活性的多肽衍生物、纳米纤维及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0105014B1 (en) * | 1982-09-24 | 1992-05-20 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Repair of tissue in animals |
DE3587022T2 (de) * | 1984-02-17 | 1993-06-17 | Genentech Inc | Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren. |
NZ226171A (en) * | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
-
1987
- 1987-12-22 US US07/136,399 patent/US4874746A/en not_active Expired - Lifetime
-
1988
- 1988-12-20 JP JP89501944A patent/JPH03501973A/ja not_active Expired - Lifetime
- 1988-12-20 JP JP1501944A patent/JPH0649657B2/ja not_active Expired - Lifetime
- 1988-12-20 EP EP89901681A patent/EP0394349B1/en not_active Expired - Lifetime
- 1988-12-20 WO PCT/US1988/004557 patent/WO1989005656A1/en active IP Right Grant
- 1988-12-20 KR KR1019890701555A patent/KR900700128A/ko not_active Application Discontinuation
- 1988-12-20 DE DE89901681T patent/DE3885300T2/de not_active Expired - Lifetime
- 1988-12-21 CN CN88109273A patent/CN1027136C/zh not_active Expired - Lifetime
- 1988-12-21 CA CA000586562A patent/CA1322164C/en not_active Expired - Lifetime
- 1988-12-21 NZ NZ227429A patent/NZ227429A/xx unknown
- 1988-12-21 IE IE383388A patent/IE61283B1/en not_active IP Right Cessation
- 1988-12-22 MX MX14307A patent/MX164966B/es unknown
- 1988-12-22 ZA ZA889594A patent/ZA889594B/xx unknown
-
1989
- 1989-08-22 DK DK198904122A patent/DK175947B1/da not_active IP Right Cessation
- 1989-08-22 OA OA59630A patent/OA09129A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
MX164966B (es) | 1992-10-09 |
KR900700128A (ko) | 1990-08-11 |
NZ227429A (en) | 1991-01-29 |
DK412289A (da) | 1989-10-19 |
EP0394349B1 (en) | 1993-10-27 |
OA09129A (en) | 1991-10-31 |
DK412289D0 (da) | 1989-08-22 |
JPH0649657B2 (ja) | 1994-06-29 |
DK175947B1 (da) | 2005-08-08 |
CA1322164C (en) | 1993-09-14 |
CN1036332A (zh) | 1989-10-18 |
US4874746A (en) | 1989-10-17 |
EP0394349A1 (en) | 1990-10-31 |
DE3885300T2 (de) | 1994-05-05 |
DE3885300D1 (de) | 1993-12-02 |
EP0394349A4 (en) | 1990-12-12 |
ZA889594B (en) | 1989-09-27 |
JPH01502180A (ja) | 1989-08-03 |
IE883833L (en) | 1989-06-22 |
JPH03501973A (ja) | 1991-05-09 |
IE61283B1 (en) | 1994-10-19 |
WO1989005656A1 (en) | 1989-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1027136C (zh) | 伤口的愈合 | |
US5035887A (en) | Wound healing composition of IL-1 and PDGF or IGF-1 | |
EP0382841B1 (en) | Wound healing | |
CN1027346C (zh) | 制备用于治疗伤口的组合物的方法 | |
US5019559A (en) | Wound healing using PDGF and IGF-II | |
US4861757A (en) | Wound healing and bone regeneration using PDGF and IGF-I | |
EP0527787B1 (en) | Method of predisposing mammals to accelerated tissue repair | |
EP0419534B1 (en) | Wound healing | |
EP0479799B1 (en) | Wound healing | |
EP0531425A4 (en) | Wound healing | |
AU613776B2 (en) | Wound healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
OR01 | Other related matters | ||
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |